


細胞治療・再生治療開発への挑戦

細胞育成学連続講演会2011


このシリーズでは、京都大学内外で細胞治療・再生治療の研究、臨床をされている先生方に、最先端の話題を提供していただきます。また、細胞治療を支える細胞治療センターの重要な役割にスポットをあてます。学生、教員の皆様の聴講を歓迎致します。

場所: 人間健康科学科 高井ホール(171号室)
日時: 毎週水曜日 16:30~18:00 (計14回)

- ◇ 10月 5日(水): 前川 平 (京都大学医学部附属病院 輸血細胞治療部 教授)
京都大学における細胞治療・再生治療開発への挑戦ー概論ー
- ◇ 10月12日(水): 笠井 泰成 (京都大学医学部附属病院 分子細胞治療センター
主任技師)
細胞治療における臨床検査技師の役割
- ◇ 10月19日(水): 伊藤 達也 (京都大学医学部附属病院 探索医療センター 助教)
治験、臨床試験に関わる規制について
- ◇ 10月26日(水): 岩田 博夫 (京都大学 再生医科学研究所 教授)
人工材料への細胞の接着
- ◇ 11月 2日(水): 川真田 伸 ((財)先端医療振興財団 再生医療支援グループ GL)
CPCの運営コストと事業化について -神戸での取り組み-
- ◇ 11月 9日(水): 神田 輝 (愛知県がんセンター研究所・腫瘍ウイルス学部 室長)
ウイルス抗原・がん抗原に特異的なT細胞を用いた細胞療法
- ◇ 11月16日(水): 仙石 慎太郎 (京都大学 細胞-物質統合拠点 (iCeMS) 准教授)
幹細胞の品質評価・安定培養技術とイノベーション
- ◇ 11月30日(水): 森本 尚樹 (京都大学医学部附属病院 形成外科 講師)
自家培養真皮を用いた皮膚潰瘍治療
- ◇ 12月 7日(水): 門脇 則光 (京都大学医学部附属病院 血液・腫瘍内科 准教授)
癌免疫療法としての細胞療法
- ◇ 12月14日(水): 青井 貴之 (京都大学 iPS細胞研究所 教授)
細胞治療に向けたiPS細胞の現状と課題
- ◇ 12月21日(水): 井家 益和 ((株)J-TEC製品開発部 部長)
ヒト細胞を組み込んだ日本初の再生医療製品の開発
- ◇ 1月 4日(水): 青山 朋樹 (京都大学大学院医学研究科人間健康科学系専 准教授)
間葉系幹細胞を用いた臨床応用
- ◇ 1月11日(水): 細田 公則 (京都大学大学院医学研究科人間健康科学系専攻 教授)
iPS細胞由来脂肪細胞を用いた脂肪萎縮症の成因解明、および細胞治療法の開発
- ◇ 1月18日(水): 一山 智 (京都大学医学部附属病院 検査部 教授)
免疫不全患者における感染症の診断と治療





**** 講義風景 ****




臨床検査展開学演習 <i>Seminar for Innovational Laboratory Medicine</i>				区 分		専門実践科目	
				所 属		職 名	氏 名
				医療検査展開学講座		教 授	高桑徹也
				医療検査展開学講座		准教授	伊吹謙太郎
単 位 数	2 単位	授業形態	演習	理学療法学講座		准教授	青山朋樹
時 間 数	30 時間	対象回生	1 回生	臨床看護学講座		教 授	細田公則
開 講 期	後期	必修・選択	必修	輸血細胞治療部		教 授	前川 平
				血液・腫瘍内科		講 師	門脇則光
				移植外科		助 教	興津 輝
				形成外科		講 師	森本尚樹
				探索医療センター		助 教	伊藤達也
				輸血細胞治療部		主任技師	笠井泰成
				再生医科学研究所		教務補佐	上田路子
授業概要と学習目標 細胞治療とは、ヒトの細胞を輸注、移植することによって行う治療法の総称であり、従来から行われている輸血治療を原型とし、造血幹細胞移植、細胞移入免疫療法、遺伝子治療、再生医療などがこれに含まれます。細胞治療の今後の発展性を考えると、「細胞育成」という役割を持つ人材が必要不可欠で、これは臨床検査技術学を主体とした領域となると考えられます。求められる能力は、単に細胞が培養できるというだけでなく、1. 細胞治療の基礎知識、理解、2. 細胞治療センター(CPC)の運営管理の考え方の理解と実践、3. 安全な細胞の育成、調製法の理解と実践、さらには、4. 細胞治療研究に必要な基礎技術の修得、5. 細胞治療研究の実際と多岐にわたります。当コースでは、細胞治療の最先端について学ぶとともに、細胞治療を背後で支える細胞治療センターの紹介、見学、実際の運営法等について学びます。							
授業計画と内容							
1 ガイダンス:細胞育成士とは				高桑徹也、 青山朋樹			
2 細胞治療・再生治療とは -研究成果を患者さんに届けるために今何が必要か-				前川 平			
3 GMPに準拠したCPCについての概念、運営法、実際1				笠井泰成			
4 GMPに準拠したCPCについての概念、運営法、実際2				笠井泰成			
5 GMPに準拠したCPCについての概念、運営法、実際3				笠井泰成			
6 新しい治療における法制度について(GCP)				伊藤達也			
7 病院における感染症の問題点				伊吹謙太郎			
8 移植外科:糖尿病に対する膵島移植				興津 輝			
9 整形外科:大腿骨頭壊死に対する間葉系幹細胞移植				青山朋樹			
10 血液内科:培養樹状細胞を用いた白血病治療				門脇則光			
11 形成外科:自家培養真皮を用いた皮膚潰瘍治療				森本尚樹			
12 内分泌内科:iPS 細胞を用いた脂質代謝異常の解明				細田公則			
13 細胞育成士の実際				上田路子			
成 績 評 価				レポート、出席			
教 科 書				無し			

細胞育成学実践論実習風景

無菌培養の基礎




機器説明







試薬説明、ロット管理





無菌培養の実践講義



細胞培養実習



品質管理



CPC(FIT)見学



研究成果の刊行に関する一覧表（英文）

	発表者氏名	論文タイトル名	発表誌名	巻名	ページ	出版年
1	Tsubakimoto Y, Yamada H, Yokoi H, Kishida S, Takata H, Kawahito H, Matsui A, Urano N, Nozawa Y, Hirai H, Imanishi J, Ashihara E, <u>Maekawa T</u> , Takahashi T, Okigaki M, Matsubara H	Bone marrow angiotensin AT1 receptor on bone marrow stem cells that regulates monocyte/macrophage lineage differentiation from hematopoietic stem	Arterioscler Thromb Vasc Biol	29	1529-1536	2009
2	Yuasa T, Sato K, Ashihara E, Takeuchi M, Malta S, Tsuchiya N, Habuchi T, <u>Maekawa T</u> , Kimura S	Intravesical administration of $\gamma\delta$ T cells successfully prevents the growth of bladder cancer in the murine model	Cancer Immunol Immunother	58	493-502	2009
3	Koto K, Horie N, Kimura S, Murata H, Sakabe T, Matsui T, Koto K, Watanabe M, Adachi S, <u>Maekawa T</u> , Fushiki S, Kubo T	Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model	Cancer Lett	274	271-278	2009
4	Ashihara E, Kawata E, Nakagawa Y, Shimazaki C, Kuroda J, Tanaka R, Yokota A, Murotani Y, Takeuchi M, Kamitsuji Y, Inaba T, Taniwaki M, Kimura S, <u>Maekawa T</u>	beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model	Clin Cancer Res	15	2731-2738	2009
5	Takeuchi M, Kimura S, Ashihara E, <u>Maekawa T</u>	Dual BCR-ABL/LYN tyrosine kinase inhibitor INNO-406	Drug of the Future	34(4)	261-269	2009
6	Kaido T, Egawa H, Tsuji H, Ashihara E, <u>Maekawa T</u> , Uemoto S	In-hospital mortality in adult recipients of living donor liver transplantation: experience of 576 consecutive cases at a single center	Liver Transpl	15	1420-1425	2009
7	Matsumoto S, Tanaka F, Sato K, Kimura S, <u>Maekawa T</u> , Hasegawa S, Wada H	Monitoring with a non-invasive bioluminescent in vivo imaging system of pleural metastasis of lung carcinoma	Lung Cancer	66	75-79	2009
8	Kitaori T, Ito H, Yoshitomi H, <u>Aoyama T</u> , Fujii T, Mimori T, Nakamura T	Severe erosive arthropathy requiring surgical treatments in systemic lupus erythematosus.	Mod Rheumatol	19	431-436	2009
9	<u>Takakuwa T</u> , Miyauchi A, Aozasa K	Aberrant somatic hypermutations in thyroid lymphomas	Leukemia Research	33	649-654	2009

研究成果の刊行に関する一覧表（英文）

	発表者氏名	論文タイトル名	発表誌名	巻名	ページ	出版年
10	Oji Y, Kitamura Y, Kamino E, Kitano A, Sawabata N, Inoue M, Mori M, Nakatsuka S, Sakaguchi N, Miyazaki K, Nakamura M, Fukuda I, Nakamura J, Tatsumi N, <u>Takakuwa T</u> , Nishida S, Shirakata T, Hosen N, Tsuboi A, Nezu R, Maeda H, Oka Y, Kawase I, Aozasa K, Okumura M, Miyoshi S, Sugiyama H	WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor	Int J Cancer	125	381-387	2009
11	Yokoi H, Yamada H, Tsubakimoto Y, Takata H, Kawahito H, Kishida S, Kato T, Matsui A, Hirai H, Ashihara E, <u>Maekawa T</u> , Iwai M, Horiuchi M, Ikeda K, Takahashi T, Okigaki M, Matsubara H	Bone marrow AT1 augments neointima formation by promoting mobilization of smooth muscle progenitors via platelet-derived SDF-1a.	Arterioscler Thromb Vasc Biol	30	60-67	2010
12	Ryu K, Murata H, Koto K, Horie N, Matsui T, Nishigaki Y, Sakabe T, Takeshita H, Itoi M, Kimura S, Ashihara E, <u>Maekawa T</u> , Fushiki S, Kubo T.	Combined effects of bisphosphonate and radiation on osteosarcoma cells	Anticancer Research	30(7)	2713-2720	2010
13	Kamio N, Hirai H, Ashihara E, Tenen DG, <u>Maekawa T</u> , Imanishi J	Use of bicistronic vectors in combination with flow cytometry to screen for effective small interfering RNA target sequences	Biochem Biophys Res Commun	393(3)	498-503	2010
14	Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T, Takeuchi M, Yao H, Reule M, Smyth T, Lyons JF, Thompson NT, Ashihara E, Ottmann OG, Maekawa T.	Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells	Blood	116(12)	2089-2095	2010
15	Kawata E, Ashihara E, Nakagawa Y, Kiuchi T, Ogura M, Yao H, Sakai K, Tanaka R, Nagao R, Yokota A, Takeuchi M, Kimura S, Hirai H, <u>Maekawa T</u> .	A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro.	Cancer Lett	294	245-253	2010

研究成果の刊行に関する一覧表（英文）

	発表者氏名	論文タイトル名	発表誌名	巻名	ページ	出版年
16	Takeuchi M, Ashihara E, Yamazaki Y, Kimura S, Nakagawa Y, Tanaka R, Yao H, Nagao R, Hayashi Y, Hirai H, Maekawa T.	Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells.	Cancer Sci	102	591-596	2010
17	Takeuchi M, Kimura S, Kuroda J, Ashihara E, Kawatani M, Osada H, Umezawa K, Yasui E, Imoto M, Tsuruo T, Yokota A, Tanaka T, Nagao R, Nakahata T, Fujiyama Y, Maekawa T.	Glyoxalase-I is novel target Bcr-Abl(+) leukemic cells acquiring stem like characteristics in a hypoxic environment.	Cell Death Differ	17	1211-1220	2010
18	Ashihara E, Kawata E, Maekawa T	Future prospect of RNA interference for cancer therapies	Curr Drug Targets	11	345-360	2010
19	Ohsaka A, Kikuta A, Ohto H, Ohara A, Ishida A, Osada K, Kimitamari A, Iwai A, Kai T, Maekawa T, Hoshi Y	Guidelines for safety management of granulocyte transfusion in Japan	Int J Hematol	91	201-208	2010
20	Taniguchi K, Shimazaki C, Ochiai N, Maruya E, Akatsuka Y, Ashihara E, Maekawa T, Taniwaki M, Saji H	Modified ELISPOT assay may predict T-cell hyporesponsiveness to non-inherited maternal antigens	Int J Lab Hematol	32	163-168	2010
21	Hamaguchi M, Seno T, Yamamoto A, Kohno M, Kadoya M, Ishino H, Ashihara E, Kimura S, Tsubakimoto Y, Takata H, Yoshikawa T, Maekawa T, Kawahito Y.	Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation.	Journal of Clinical Biochemistry and Nutrition	47	138-147	2010
22	Yokota A, Kimura S, Tanaka R, Takeuchi M, Yao H, Sakai K, Nagao R, Kuroda J, Kamitsuji Y, Kawata E, Ashihara E, Maekawa T	Osteoclasts are involved in the maintenance of dormant leukemic cells	Leuk Res	34	793-799	2010
23	Ushiki T, Kizaka-Kondoh S, Ashihara E, Tanaka S, Masuko M, Hirai H, Kimura S, Aizawa Y, Maekawa T, Hiraoka M.	Noninvasive tracking of donor cell homing by near-infrared fluorescence imaging shortly after bone marrow transplantation.	PLOS One	5:e11114	1-12	2010

研究成果の刊行に関する一覧表（英文）

	発表者氏名	論文タイトル名	発表誌名	巻名	ページ	出版年
24	Ito K, <u>Aoyama T</u> , Fukiage K, Otsuka S, Furu M, Jin Y, Nasu A, Ueda M, <u>Kasai Y</u> , Ashihara E, Kimura S, <u>Maekawa T</u> , Kobayashi A, Yoshida S, Niwa H, Otsuka T, Nakamura T, Toguchida J	A novel method to isolate mesenchymal stem cells from bone marrow in a closed system using a device made by nonwoven fabric	Tissue Eng Part C Methods	16	81-91	2010
25	Sekimoto M, Imanaka Y, Shirai T, Sasaki H, Komeno T, Lee J, Yoshihara K, Ashihara E, <u>Maekawa T</u>	Risk-adjusted assessment of incidence and quantity of blood use in acute-care hospitals in Japan: an analysis using administrative data	Vox Sanguinis	98(4)	538-546	2010
26	Jin Y, Shima Y, Furu M, <u>Aoyama T</u> , Nakamata T, Nakayama T, Nakamura T, Toguchida J	Absence of Oncogenic Mutations of RAS Family Genes in Soft Tissue Sarcomas of 100 Japanese Patients	Anticancer Res	30(1)	245-252	2010
27	Jin Y, Kato T, Furu M, Nasu A, Kajita Y, Mitsui H, Ueda M, <u>Aoyama T</u> , Nakayama T, Nakamura T, Toguchida J.	Mesenchymal stem cells cultured under hypoxia escape from senescence via down-regulation of p16 and extracellular signal regulated kinase.	Biochem Biophys Res Commun	391	1471-1476	2010
28	Yamada M, Tanaka B, Nagai K, <u>Aoyama T</u> , Ichihashi N.	Trail-Walking Exercise and Fall Risk Factors in Community-Dwelling Older Adults: Preliminary Results of a Randomized Controlled Trial.	J Am Geriatr Soc	58	1946-1951	2010
29	<u>Aoyama T</u> , Okamoto T, Fukiage K, Otsuka S, Furu M, Ito K, Jin Y, Ueda M, Nagayama S, Nakayama T, Nakamura T, Toguchida J.	Histone modifiers, YY1 and p300, regulate the expression of cartilage-specific gene, chondromodulin-I, in mesenchymal stem cells.	J Biol Chem	285	29842-29850	2010
30	Kaszynski RH, Akatsuka S, Hiratsuka T, Jin G, Ozeki M, Okuno T, Nakamura T, Manabe T, <u>Takakuwa T</u> , Hiai H, Toyokuni S, Tamaki K, Tsuruyama T	A Quantitative trait locus responsible for inducing B-cell lymphoblastic lymphoma is a hotspot for microsatellite instability	Cancer Sci	101	800-805	2010
31	Tsuruyama T, Imai Y, Takeuchi H, Hiratsuka T, Maruyama Y, Kanaya K, Kaszynski R, Jin G, Okuno T, Ozeki M, Nakamura T, <u>Takakuwa T</u> , Manabe T, Tamaki K, Hiai H	Dual retrovirus integration tagging: identification of new signaling molecules Fiz1 and Hipk2 that are involved in the IL-7 signaling pathway in B lymphomas	J Leukoc Biol	88(1)	107-115	2010

研究成果の刊行に関する一覧表（英文）

	発表者氏名	論文タイトル名	発表誌名	巻名	ページ	出版年
32	Inaba K, Fukazawa Y, Matsuda K, Himeno A, Matsuyama M, <u>Ibuki K</u> , Miura Y, Koyanagi Y, Nakajima A, Blumberg RS, Takahashi H, Hayami M, Igarashi T, Miura T	Small intestine CD4+ cell reduction and enteropathy in SHIV-KS661-infected rhesus macaques in presence of low viral load	J Gen Virol	91	773-781	2010
33	Himeno A, Akagi T, Uto T, Wang X, Baba M, <u>Ibuki K</u> , Matsuyama M, Horiike M, Igarashi T, Miura T, Akashi M.	Evaluation of the immune response and protective effects of rhesus macaques vaccinated with biodegradable nanoparticles carrying gp120 of human immunodeficiency virus.	Vaccine	28	5377-5385	2010
34	Matsuda K, Inaba K, Fukazawa Y, Matsuyama M, <u>Ibuki K</u> , Horiike M, Saito N, Hayami M, Igarashi T, Miura T.	In vivo analysis of a new R5 tropic SHIV generated from the highly pathogenic SHIV-KS661, a derivative of SHIV-89.6.	Virology	399	134-143	2010
35	Yao H, Ashihara E, Strovel JW, Nakagawa Y, Kuroda J, Nagao R, Tanaka R, Yokota A, Takeuchi M, Sakai K, Shimazaki C, Taniwaki M, Strand K, Padia J, Hirai H, Kimura S, Maekawa T.	AV-65, a novel Wnt/ β -catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model.	Blood Cancer Journal	1(e43)	1-9	2011
36	Kitawaki T, Kadowaki N, Fukunaga K, <u>Kasai Y</u> , <u>Maekawa T</u> , Ohmori K, Kondo T, Maekawa R, Takahara M, Nieda M, Kuzushima K, Ishikawa T, Uchiyama T.	A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate.	Brit J Haematol	153	796-799	2011
37	Nagao R, Ashihara E, Kimura S, Strovel JW, Yao H, Takeuchi M, Tanaka R, Hayashi Y, Hirai H, Padia J, Strand K, Maekawa T.	Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65, a novel Wnt/ β -catenin signaling inhibitor.	Cancer Lett	312	91-100	2011
38	Tanaka R, Kimura S, Ashihara E, Yoshimura M, Takahashi N, Wakita H, Itoh K, Nishiwaki K, Suzuki K, Nagao R, Yao H, Hayashi Y, Satake S, Hirai H, Sawada K-I, Ottmann OG, Melo JV, Maekawa T.	Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients.	Cancer Lett	312	228-234	2011

研究成果の刊行に関する一覧表（英文）

	発表者氏名	論文タイトル名	発表誌名	巻名	ページ	出版年
39	Takeuchi M, Ashihara E, Maekawa T, et al.	Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells.	Cancer Sci	102	591-596	2011
40	Kawatani M, Takayama H, Muroi M, Kimura S, Maekawa T, Osada H.	Identification of a small molecule inhibitor of DNA topoisomerase II by proteomic profiling.	Chem Biol	18	743-751	2011
41	Sakai K, Kawata E, Ashihara E, Nakagawa Y, Yamauchi A, Yao Y, Nagao R, Tanaka R, Yokota A, Takeuchi T, Hirai H, Kimura S, Hirashima M, Yoshimura N, Maekawa T.	Galectin-9 ameliorates acute Graft-versus-host disease through the induction of T-cell apoptosis.	Eur J Immunol	41	67-75	2011
42	Kitawaki T, Kadowaki N, Fukunaga K, Kasai Y, Maekawa T, Ohmori K, Itoh T, Shimizu A, Kuzushima K, Kondo T, Ishikawa T, Uchiyama T.	Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia.	Exp Hematol	39	424-433	2011
43	Yao H, Ashihara E, Maekawa T.	Targeting the Wnt/ β -catenin signaling pathway in human cancers.	Expert Opinion on Therapeutic Targets	15	873-887	2011
44	Yamamoto A, Ashihara E, Nakagawa Y, Obayashi H, Ohta M, Hara H, Adachi T, Seno T, Kadoya M, Hamaguchi M, Ishino H, Kohno M, Maekawa T, Kawahito Y.	Allograft inflammatory factor-1 is overexpressed and induces fibroblast chemotaxis in the skin of sclerodermatous GVHD in a murine model.	Immunol Lett	135	144-150	2011
45	Kawata E, Ashihara E, Maekawa T.	RNA interference against Polo-like kinase-1 in advanced non-small cell lung cancers.	J Clin Bioinformatics	1	1-6	2011
46	Shoji T, Bando T, Fujinaga T, Chen F, Yurugi K, Maekawa T, Date H.	ABO-incompatible living-donor lobar lung transplantation.	J Heart Lung Transplant	30	479-480	2011
47	Yamamichi J, Ojima T, Yurugi M, Iida M, Imamura T, Ashihara E, Kimura S, Maekawa T.	Single-step, label-free quantification of antibody in human serum for clinical applications based on localized surface plasmon resonance.	Nanomedicine: Nanotechnology, Biology, and Medicine	7	889-895	2011
48	Tauchi T, Okabe S, Ashihara E, Kimura S, Maekawa T, Ohayashiki K.	Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen.	Oncogene	30	2789-2797	2011

研究成果の刊行に関する一覧表（英文）

	発表者氏名	論文タイトル名	発表誌名	巻名	ページ	出版年
49	Seno T, Hamaguchi M, Ashihara E, Kohno M, Ishino H, Yamamoto A, Kadoya M, Nakamura K, Murakami K, Matoba S, <u>Maekawa T</u> , Kawahito, Y.	15-Deoxy- Δ 12,14 prostaglandin J2 reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice.	PLoS One,	6: e25541	1-10	2011
50	Yamamoto-Sugitani M, Kuroda J, Ashihara E, Nagoshi H, Kobayashi T, Matsumoto Y, Sasaki N, Kiyota M, Nakayama R, Akaji K, Taki T, Uoshima N, Kobayashi Y, Horiike S, <u>Maekawa T</u> , Taniwaki M.	Galectin-3 induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia.	Proc Natl Acad Sci USA	108	17468-17473	2011
51	Tada N, Hinotsu S, Urushihara H, Kita F, Kai S, Takahashi T, A, Kato S, Takanashi M, Ito K, Sawai H, <u>Maekawa, T</u> , Kosugi S, Kawakami K.	The current status of umbilical cord blood collection in Japanese medical centers: survey of obstetricians.	Transfusion and Apheresis Science	44	263-268	2011
52	Yamada M, <u>Aoyama T</u> , Okamoto K, Nagai K, Tanaka B, Takemura T.	Using a Smartphone while walking: a measure of dual-tasking ability as a falls risk assessment tool.	Age Ageing.	40(4)	516-519	2011
53	Yamada M, Arai H, Uemura K, Mori S, Nagai K, Tanaka B, Terasaki Y, Iguchi M, <u>Aoyama T</u> .	Effect of resistance training on physical performance and fear of falling in elderly with different levels of physical well-being.	Age Ageing.	40(5)	637-641	2011
54	Yamada M, Tanaka H, Mori S, Nagai K, Uemura K, Tanaka B, <u>Aoyama T</u> , Ichihashi N.	Fallers choose an early transfer gaze strategy during obstacle avoidance under dual-task condition.	Aging Clin Exp Res	23(4)	316-319	2011
55	Mitsui H, <u>Aoyama T</u> , Furu M, Ito K, Jin Y, Maruyama T, Kanaji T, Fujimura S, Sugihara H, Nishiura A, Otsuka T, Nakamura T, Toguchida J.	Prostaglandin E2 receptor type 2-selective agonist prevents the degeneration of articular cartilage in rabbit knees with traumatic instability.	Arthritis Res Ther	13	R146(1-13)	2011
56	Yamada M, <u>Aoyama T</u> , Arai H.	Tailor-made programs for preventive falls that match the level of physical well-being in community-dwelling olderadults.	Geriatrics	8	118-132	2011
57	Yamada M, <u>Aoyama T</u> , Nakamura M, Tanaka B, Nagai K, Tatematsu N, Uemura K, Nakamura T, Tsuboyama T, Ichihashi N.	The Reliability and Preliminary Validity of Game-Based Fall Risk Assessment in Community-Dwelling Older Adults.	Geriatr Nurs	32(3)	188-194	2011

研究成果の刊行に関する一覧表（英文）

	発表者氏名	論文タイトル名	発表誌名	巻名	ページ	出版年
58	Yamada M, <u>Aoyama T</u> , Arai H, Nagai K, Tanaka B, Uemura K, Mori S, Ichihashi N.	Dual-task walk is a reliable predictor of falls in robust elderly adults.	J Am Geriatr Soc	59(1)	163-164	2011
59	Yamada M, Arai H, Nagai K, Uemura K, Mori S, <u>Aoyama T</u> .	Differential determinants of physical daily activities in frail and nonfrail community-dwelling older adults.	Journal Of clinical Gerontology & Geriatrics	2	42-46	2011
60	Yamada M, Higuchi T, Tanaka B, Nagai K, Uemura K, <u>Aoyama T</u> , Ichihashi N.	Measurements of Stepping Accuracy in a Multitarget Stepping Task as a Potential Indicator of Fall Risk in Elderly Individuals.	J Gerontol A Biol Sci Med Sci.	66(9)	994-1000	2011
61	Furu M, Kajita Y, Nagayama S, Ishibe T, Shima Y, Nishijo K, Uejima D, Takahashi R, <u>Aoyama T</u> , Nakayama T, Nakamura T, Nakashima Y, Ikegawa M, Imoto S, Katagiri T, Nakamura Y, Toguchida J.	Identification of AFAP1L1 as a prognostic marker for spindle cell sarcomas.	Oncogene	30(38)	4015-4025.	2011
62	Ota M, Neo M, <u>Aoyama T</u> , Ishizaki T, Fujibayashi S, Takemoto M, Nakayama T, Nakamura T.	Impact of the O-C2 angle on the oropharyngeal space in normal subjects.	Spine	36	E720-E726	2011
63	Tsuruyama T, Maruyama Y, Kanaya K, <u>Takakuwa T</u> et al.	Murine Leukemia Retrovirus Integration Induces the Formation of Transcription Factor Complexes on Palindromic Sequences in the Signal Transducer and Activator of Transcription Factor 5a Gene During the Development of Pre-B Lymphomagenesis.	Am J Pathol	178(3)	1374-1386	2011
64	<u>Takakuwa T</u> .	Pyothorax-associated lymphoma: Loss of Epstein-Barr virus nuclear antigen-3B protein expression as a result of mismatch repair phenotypes.	Kenkou Kagaku	7	17-22	2011
65	Ban H, Nishishita N, Fusaki N, Tabata T, Saeki K, Shikamura M, Takada N, Inoue M, Hasegawa M, <u>Kawamata S</u> , Nishikawa S.	Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors	Proc.Nat.Aca.Sci.	108(34)	14234-14239	2011

研究成果の刊行に関する一覧表（英文）

	発表者氏名	論文タイトル名	発表誌名	巻名	ページ	出版年
66	Nishishita N, Ijiri H, Takenaka C, Kobayashi K, Goto K, Kotani E, Itoh T, Mori H, <u>Kawamata S</u> .	The use of leukemia inhibitory factor immobilized on virus-derived polyhedra to support the proliferation of mouse embryonic and induced pluripotent stem cells.	Biomaterials	32	3555-3563	2011
67	Maita S, Yuasa T, Tsuchiya N, Mitobe Y, Narita S, Horikawa Y, Hatake K, Fukui I, Kimura S, <u>Maekawa T</u> , Habuchi T.	Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int J Cancer,	Int J Cancer	130	677-684	2012
68	Hirose A, Yamada S, <u>Takakuwa T</u> et al.	Embryonic liver morphology and morphometry by magnetic resonance microscopic imaging.	Anat Rec (Hoboken)	295(1)	51-59	2012
69	Yamada M, Higuchi T, Mori S, Uemura K, Nagai K, <u>Aoyama T</u> , Ichihashi N.	Maladaptive turning and gaze behavior induces impaired stepping on multiple footfall targets during gait in older individuals who are at high risk of falling.	Arch Gerontol Geriatr.	54(2)	e102-e108	2012
70	Yamada M, Uemura K, Mori S, Nagai K, Uehara T, Arai H, <u>Aoyama T</u> .	Faster decline of physical performance in older adults with higher levels of baseline locomotive function.	Geriatr Gerontol Int	12	238-246	2012
71	Yamada S, <u>Takakuwa T</u> et al.	Introduction- development of the human embryos.	The Human Embryo. Open Access Publisher, Rijeka, Croatia.	1	3-20	2011
72	Yamada S, <u>Takakuwa T</u> et al.	Developmental Anatomy of the Human Embryo-3D-Imaging and Analytical Techniques.	The Human Embryo. Open Access Publisher, Rijeka, Croatia.	7	111-126	2012
73	Nakashima T, Yamada S, <u>Takakuwa T</u> et al.	Morphometric analysis of the brain vesicles during the human embryonic period by magnetic resonance microscopic imaging.	Congenital Anomalies	52	55-58	2012
74	Kagurasho M, Yamada S, <u>Takakuwa T</u> et al.	Movement of the external ear in human embryo.	Head Face Med	8:2	3-9	2012
75	Yamada M, <u>Aoyama T</u> , Tanaka B, Nagai K, Ichihashi N.	Seated stepping exercise under a dual-task condition improves ambulatory function with a secondary task: a randomized controlled trial.	Aging Clin Exp Res			2011(in press)
76	Yamada M, <u>Aoyama T</u> , Mori S, Nishiguchi S, Okamoto K, Ito T, Muto S, Ishihara T, Yoshitomi H, Ito H.	Objective assessment of abnormal gait in patients with rheumatoid arthritis using a smartphone.	Rheumatol Int.		1-6	2011(in press)

研究成果の刊行に関する一覧表（英文）

	発表者氏名	論文タイトル名	発表誌名	巻名	ページ	出版年
77	Nishishita N, Takenaka C, <u>Kawamata S.</u>	Generation, Maintenance and Differentiation of iPS cells from Cord Blood Cells.	Human Embryonic and Induced Pluripotent Stem Cells.(Lineage-Specific Differentiation Protocols Published by Springer)			in press
78	Nishishita N, Takenaka C, Fusaki N, <u>Kawamata S.</u>	Generation of Human Induced Pluripotent Stem Cells from Cord Blood Cells.	Pluripotent Stem Cells, <i>Nova Science Publishers, Inc.</i>			in press
79	Kurata R, Fujita F, Oonishi K, Kuriyama K, <u>Kawamata S.</u>	Identification of novel factors which enhance melanogenesis in keratinocyte-melanocyte Co-culture.	ASCS			in press

研究成果の刊行に関する一覧表（和文）

	発表者氏名	論文タイトル名	発表誌名	巻名	ページ	出版年
1	八尾尚幸、前川 平	造血器腫瘍治療における輸血療法の適応は？特集「支持療法・輸血」	EBM 血液疾患の治療2010-2011		493-497	2009
2	万木紀美子、前川 平	IV. 血液製剤 2) 輸血療法の実際	総合臨床第58巻増刊号「今すぐに役立つ 輸液ガイドブック」	58	390-398	2009
3	八尾尚幸、芦原英司、前川平	支持療法－輸血・成分輸血、Epo, G-CSFなど。特集「骨髄性白血病－病因・治療研究の進歩」	日本臨床	67	1951-1957	2009
4	青山朋樹、戸口田淳也	間葉系幹細胞	幹細胞の分化誘導と応用		55-61	2009
5	青山朋樹、戸口田淳也、中村孝志	間葉系幹細胞を利用した大腿骨頭無腐性壊死の再生医療技術	幹細胞の分化誘導と応用		262-7	2009
6	青山朋樹、笠井泰成、上田路子、前川 平、中村孝志、戸口田淳也。	大腿骨頭無腐性壊死症に対する自己骨髄間葉系幹細胞を用いた臨床試験：細胞調製の安全性管理体制に関して	再生医療	9	25-31	2010
7	芦原英司、前川 平。	悪性腫瘍に対するsiRNA療法。最新RNAと疾患研究2009。第3章 RNA研究から臨床へ。中村義一 編。	メディカルドゥ		139-146	2010
8	務中達也、叶井正樹、木村晋也、芦原英司、阿部浩久、庄司習一、前川平	細胞解析チップ－生体内のがん細胞の挙動研究を目指して－。	島津評論	66	141-149	2010
9	青山朋樹、戸口田淳也	プロスタグランジンE2受容体特異的作動薬	整形外科	61	268	2010
10	中村孝志（分担執筆：青山朋樹）	臨床医学の展望 整形外科学	日本医事新報	4478	78-79	2010
11	青山朋樹、戸口田淳也	変形性股関節症に対する再生治療	Medical Rehabilitation	123	65-69	2010
12	笠井泰成。	細胞プロセッシングセンター(CPC)における臨床検査技師の役割 - 細胞治療の臨床応用に向けて。	検査と技術	38	1246-1249	2010
13	青山朋樹、前川平、中村孝志、戸口田淳也。	間葉系幹細胞を用いた骨壊死治療。	オルソタオムズ	5(3)	2	2011

研究成果の刊行に関する一覧表（和文）

14	藤原晴美、渡邊弘子、山田千亜希、大友直樹、押田眞知子、友田豊、万木紀美子、星順隆、高橋孝喜、前川平、大戸斉、竹下明裕.	大学病院輸血部門の技師が輸血医学教育において果たす役割とその重要性；平成21年度大学病院輸血部会議「教育に関する調査報告」（1）	日本輸血細胞治療学会誌	57（6）	470-477	2011
15	青山朋樹、笠井泰成、上田路子、井沼俊明、高橋稔、海平和男、山田実、戸口田淳也、前川平.	再生医療に用いる生体由来物搬送容器ユニットの開発.	バイオインダストリー	28(5)	29-34	2011
16	前川平	第33回日本造血細胞移植学会 細胞移植・治療 各種指針を順守して、健全な発展を	Medical Tribune	6月16日号	30-31	2011
17	木村貴文、前川平.	〈記録〉第31回日本臨床薬理学会年会 2010年12月1～3日京都 シンポジウム3：細胞治療 座長のまとめ	臨床薬理	42(3)	133-134	2011
18	青山朋樹、笠井泰成、上田路子、前川平、中村孝志、戸口田淳也.	軟治性骨壊死疾患に対する間葉系幹細胞を用いた臨床試験	臨床薬理	42(3)	137-138	2011
19	青山朋樹.	骨壊死の治療に間葉系幹細胞はどこまで有効か.	整形外科	62(13)	1394	2011
20	戸口田淳也、青山朋樹、後藤公志、柿木良介、笠井泰成.	大腿骨頭無腐性壊死症に対する細胞治療.	日本臨床	69(12)	2225-2230	2011
21	永井宏達、山田実、上村一貴、森周平、青山朋樹、市橋則明、坪山直生.	姿勢制御エクササイズの反復が足関節における筋の同時活動に及ぼす影響.	理学療法学	38(2)	84-89.	2011

Bone Marrow Angiotensin AT₁ Receptor Regulates Differentiation of Monocyte Lineage Progenitors From Hematopoietic Stem Cells

Yoshinori Tsubakimoto, Hiroyuki Yamada, Hirokazu Yokoi, Sou Kishida, Hiroki Takata, Hiroyuki Kawahito, Akihiro Matsui, Norifumi Urao, Yoshihisa Nozawa, Hideyo Hirai, Jiro Imanishi, Eishi Ashihara, Taira Maekawa, Tomosaburo Takahashi, Mitsuhiko Okigaki, Hiroaki Matsubara

Background—The angiotensin II (Ang II) type 1 (AT₁) receptor is expressed in bone marrow (BM) cells, whereas it remains poorly defined how Ang II regulates differentiation/proliferation of monocyte-lineage cells to exert proatherogenic actions.

Methods and Results—We generated BM chimeric apoE^{-/-} mice repopulated with AT₁-deficient (Agtr1^{-/-}) or wild-type (Agtr1^{+/+}) BM cells. The atherosclerotic development was significantly reduced in apoE^{-/-}/BM-Agtr1^{-/-} mice compared with apoE^{-/-}/BM-Agtr1^{+/+} mice, accompanied by decreased numbers of BM granulocyte/macrophage progenitors (GMP:c-Kit⁺Sca-1⁻Lin⁻CD34⁺CD16/32⁺) and peripheral blood monocytes. Macrophage-colony-stimulating factor (M-CSF)-induced differentiation from hematopoietic stem cells (HSCs:c-Kit⁺Sca-1⁺Lin⁻) to promonocytes (CD11b^{high}Ly-6G^{low}) was markedly reduced in HSCs from Agtr1^{-/-} mice. The expression of M-CSF receptor c-Fms was decreased in HSCs/promonocytes from Agtr1^{-/-} mice, accompanied by a marked inhibition in M-CSF-induced phosphorylation of PKC- δ and JAK2. c-Fms expression in HSCs/promonocytes was mainly regulated by TNF- α derived from BM CD45⁻CD34⁻ stromal cells, and Ang II specifically regulated the TNF- α synthesis and release from BM stromal cells.

Conclusions—Ang II regulates the expression of c-Fms in HSCs and monocyte-lineage cells through BM stromal cell-derived TNF- α to promote M-CSF-induced differentiation/proliferation of monocyte-lineage cells and contributes to the proatherogenic action. (*Arterioscler Thromb Vasc Biol.* 2009;29:1529-1536.)

Key Words: bone marrow progenitors ■ angiotensin ■ monocyte ■ atherosclerosis ■ M-CSF

The angiotensin II (Ang II) type 1 (AT₁) receptor exerts proatherogenic actions.¹ AT₁ receptor-deficient (Agtr1^{-/-}) mice showed a significant reduction of atherosclerotic development,^{2,3} and treatment with AT₁ receptor blocker (ARB) reduced the size of atherosclerotic lesions both in experimental animals and humans.⁴ AT₁ receptors are present in a variety of cells, including endothelial cells, vascular smooth muscle cells, and bone marrow (BM) stem cells and progenitors.^{5,6} Recently, Cassis et al demonstrated that Ang II-induced atherosclerosis was significantly attenuated in LDL receptor-deficient (LDLr^{-/-}) mice whose BM cells were repopulated with Agtr1^{-/-} cells.⁷ Fukuda et al also reported that atherosclerotic lesion development was significantly reduced in apoE-deficient (apoE^{-/-}) mice with Agtr1^{-/-} marrow.⁸ However, no information regarding the role of the BM-AT₁ receptor on the differentiation/proliferation and properties of BM stem cells and progenitors has been reported in these previous studies.

Monocytes and macrophages play a crucial role in the pathogenesis of atherosclerosis, which is characterized by plaque

progression, destabilization, and subsequent plaque rupture, through foam cell formation, migration/proliferation of resident vascular smooth muscle cells, and degradation of extracellular matrix.⁹ Along with the previous studies showing the effect of diet-induced hypercholesterolemia on BM and leukocyte,¹⁰ Swirski et al reported that hypercholesterolemia induced a surprisingly profound expansion of blood monocytes as well as BM monocyte-lineage cells.¹¹ However, the relative contribution of the BM renin-angiotensin system to hypercholesterolemia-associated monocytosis has not been fully investigated.¹²

In the present study, we focused on the action of the AT₁ receptor expressed in BM cells and studied whether (1) Ang II affects the differentiation/proliferation from BM stem cells into monocyte-lineage cells, and (2) hypercholesterolemia-associated monocytosis contributes to the development of AT₁-mediated atherosclerosis. Our results demonstrated for the first time that (1) Ang II promotes M-CSF-induced differentiation from hematopoietic stem cells (HSCs; c-Kit⁺Sca-1⁺Lin⁻) into monocyte-lineage cells through up-regulation of the M-CSF receptor c-Fms, and that (2) TNF- α

Received September 28, 2008; revision accepted July 14, 2009.

From the Department of Cardiovascular Medicine (Y.T., H. Yamada, H. Yokoi, S.K., H.T., H.K., A.M., N.U., T.T., M.O., H.M.) and the Department of Microbiology (H.H., J.I.), Kyoto Prefectural University School of Medicine, Japan; Pharmacobioregulation Research Laboratory (Y.N.), Taiho Pharmaceutical Co Ltd, Inou, Japan; and the Department of Transfusion Medicine and Cell Therapy (E.A., T.M.), Kyoto University Hospital, Japan.

Correspondence to Hiroyuki Yamada, MD, PhD, Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566 Japan. E-mail hiyamada@koto.kpu-m.ac.jp

© 2009 American Heart Association, Inc.

Arterioscler Thromb Vasc Biol is available at <http://atvb.ahajournals.org>

DOI: 10.1161/ATVBAHA.109.187732




Figure 1. Attenuated atherosclerosis accompanied by the reduction of monocyte-lineage cells on ablation of marrow AT₁. **A**, Two-month-old *apoE^{-/-}* mice whose BM was repopulated with *Agtr1^{-/-}* or *Agtr1^{+/+}* cells. Quantitative analysis showing the lower area of atherosclerotic lesions in *apoE^{-/-}/BM-Agr1^{-/-}* mice than *apoE^{-/-}/BM-Agr1^{+/+}* mice. Values are the mean \pm SE for at least 8 mice in each group. **P* < 0.05 vs *apoE^{-/-}/BM-Agr1^{+/+}* mice. **B**, Flow cytometry of c-Kit and Sca-1 expression in lineage-negative BM populations and CD16/32 and CD34 expression in c-Kit⁺Sca-1⁻ lineage-negative BM populations of *apoE^{-/-}/BM-Agr1^{+/+}* and *apoE^{-/-}/BM-Agr1^{-/-}* mice fed a Western diet for 2 months. Quantitative analysis showing a decrease in GMP number in *apoE^{-/-}/BM-Agr1^{-/-}* mice. HSCs indicates hematopoietic stem cells; CMP, common myeloid progenitors; GMP, granulocyte and macrophage progenitors. Values are the mean \pm SE for at least 5 mice in each group. **P* < 0.05 vs *apoE^{-/-}/BM-Agr1^{+/+}* mice.

derived from BM CD45⁻CD34⁻ stromal cells growth-controlled by Ang II specifically regulates the c-Fms expression in promonocytes (CD11b^{high}Ly-6G^{low}), thus leading to the increased numbers of circulating monocytes that modulate AT₁-mediated proatherogenic activities.

Methods

A full description of all methods can be found in the Data Supplement (available online at <http://atvb.ahajournals.org>).

Animal Preparation

ApoE^{-/-} mice (C57BL/6) and AT1a receptor-deficient (*Agtr1^{-/-}*) mice (C57BL/6) were obtained from Taconic Co Ltd (Germantown, NY) and Tanabe Seiyaku Co Ltd (Osaka, Japan), respectively. BM cells of 2-month-old female *apoE^{-/-}* recipient mice were repopulated with male *Agtr1^{-/-}* or *Agtr1^{+/+}* cells. The percentage chimerism determined by transplanting GFP-overexpressing BM cells was 96 \pm 2% of peripheral blood mononuclear cells.¹³ Furthermore, BM CD45⁻CD34⁻ stromal cells, HSCs, and myeloid progenitors (MP: c-Kit⁺Sca-1⁻Lin⁻) were almost completely (more than 99%) replaced by GFP-positive cells (supplemental Figure I). All animal experiments were conducted according to the Guidelines for Animal Experiments at Kyoto Prefectural University School of Medicine.

Statistical Analysis

All data are expressed as the mean \pm SE. Mean values were compared using ANOVA. If a statistical significant effect was found, Fisher

test was performed to detect the difference between the groups. *P* < 0.05 was considered statistically significant.

Results

BM-AT₁ Deficiency Attenuates Atherosclerosis Concomitant With the Reduction of BM Monocyte-Lineage Cells

Consistent with the previous reports,⁸ *apoE^{-/-}/BM-Agr1^{-/-}* mice showed a significant reduction of atherosclerotic lesions compared with *apoE^{-/-}/BM-Agr1^{+/+}* mice (31%, *P* < 0.05; Figure 1A). At 3 months after BMT, the numbers of white blood cells and monocytes were similar between the 2 groups (supplemental Table I). However, after 2 months of a Western diet feeding, white blood cells and monocytes were significantly less abundant in *apoE^{-/-}/BM-Agr1^{-/-}* mice than *apoE^{-/-}/BM-Agr1^{+/+}* mice by 40% and 39%, respectively (*P* < 0.05; supplemental Table II).

HSCs (c-Kit⁺Sca-1⁺Lin⁻) have been shown to differentiate into common myeloid progenitors (CMP: c-Kit⁺Sca-1⁻Lin⁻CD34⁺CD16/32⁻) and then granulocyte/macrophage progenitors (GMP: c-Kit⁺Sca-1⁻Lin⁻CD34⁺CD16/32⁺), followed by the terminal differentiation into BM promonocytes (CD11b^{high}Ly-6G^{low}).^{14,15} We examined BM-AT₁-me-